Lung Adenocarcinoma clinical trials

Explore recruiting lung adenocarcinoma clinical trials.

Recruiting lung adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lung Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

Spain, France, Belgium, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE IB/II CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF CHEMOIMMUNOTHERAPY PLUS SHORT COURSE OF MEK INHIBITOR IN FIRST LINE OF TREATMENT OF METASTATIC NON SQUAMOUS NON SMALL CELL LUNG ADENOCARCINOMA WITH PDL1 <50%

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

Spain, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Spain, France, Netherlands, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Lung Adenocarcinoma trials by city

Lung Adenocarcinoma in Toronto Lung Adenocarcinoma in Vancouver Lung Adenocarcinoma in Montreal Lung Adenocarcinoma in Calgary Lung Adenocarcinoma in Edmonton Lung Adenocarcinoma in Ottawa Lung Adenocarcinoma in Winnipeg Lung Adenocarcinoma in Quebec City Lung Adenocarcinoma in Hamilton Lung Adenocarcinoma in Kitchener Lung Adenocarcinoma in London Lung Adenocarcinoma in Halifax Lung Adenocarcinoma in New York Lung Adenocarcinoma in Los Angeles Lung Adenocarcinoma in Chicago Lung Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease